Thalidomide-induced teratogenesis: History and mechanisms

Birth Defects Research Part C - Embryo Today: Reviews

Volumn 105, Issue 2, 2015, Pages 140-156

  Vargesson, Neil ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Actin cytoskeleton; Angiogenesis; Cell death; Cereblon; Fgf8; Limb development; Phocomelia; Reactive oxygen species; Shh; Vascular transition

Indexed keywords

GUANYLATE CYCLASE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; THALIDOMIDE; TUBULIN; TERATOGENIC AGENT;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CELL DEATH; CEREBLON GENE; CONGENITAL MALFORMATION; CROHN DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; EMBRYO DEVELOPMENT; EMBRYOPATHY; GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEPROSY; LIMB DEFECT; MORNING SICKNESS; MULTIPLE MYELOMA; NONHUMAN; PREGNANT WOMAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TERATOGENESIS; TERATOGENICITY; ABNORMALITIES, DRUG-INDUCED; ADULT; ANIMAL; DRUG EFFECTS; FEMALE; HISTORY; MALE; PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANIMALS; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; PREGNANCY; TERATOGENESIS; TERATOGENS; THALIDOMIDE;

EID: 84933182125     PISSN: 1542975X     EISSN: 15429768     Source Type: Journal    
DOI: 10.1002/bdrc.21096     Document Type: Review

References (119)

1. Arlen RR, Wells PG. 1996. Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for Prostaglandin H Synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate. J Pharm and Exp Thera (JPET) 277:1649-1658.
2. Ashby J, Tinwell H. 2002. Thalidomide is not a human mutagen. Br Med J 325:1245.
3. Ashby J, Tinwell H, Callander RD, et al. 1997. Thalidomide: lack of mutagenic activity across phyla and genetic endpoints. Mutation Res 396:45-64.
4. Bates AW. 2001. A case of roberts syndrome described in 1737. J Med Genet 38:565-567.
5. Boylen JB, Horne HH, Johnson WJ. 1963. Teratogenic effects of thalidomide and related substances. Lancet 1:552.
6. Brook CG, Jarvis SN, Newman CG. 1977. Linear growth of children with limb deformities following exposure to thalidomide in utero. Acta Paediatr Scand 66:673-675.
7. Castilla EE, Ashton-Prolla P, Barreda-Mejia E, et al. 1996. Thalidomide, a current teratogen in south america. Teratology 54:273-277.
8. Chamberlain PP, Lopez-Girona A, Miller K, et al. 2014. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol 21:803-809.
9. Cullen JF. 1964. Ocular defects in thalidomide babies. Br J Ophthalmol 48:151-153.
10. Cuthbert R, Speirs AL. 1963. Thalidomide induced malformations-a radiological survey. Clin Radiol 14:163-199.
11. D'Amato RJ, Loughnan MS, Flynn E, et al. 1994. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085.
12. Ema M, Ise R, Kato H, et al. 2010. Fetal malformations and early embryonic gene expression response in cynomolgus monkeys maternally exposed to thalidomide. Reprod Toxicol 29:49-56.
13. Feng Q, Tan HH, Ge ZZ, et al. 2014. Thalidomide-induced angiopoietin 2, Notch1 and Dll4 downregulation under hypoxic condition in tissues with gastrointestinal vascular malformation and human umbilical vein endothelial cells. J Dig Dis 15:85-95.
14. Fischer ES, Bohm K, Lydeard JR, et al. 2014. Structure of the DDB1-CRBN e3 ubiquitin ligase in complex with thalidomide. Nature 512:49-53.
15. Fort DJ, Stover EL, Bantle JA. et al. 2000. Evaluation of the developmental toxicity of thalidomide using frog embryo teratogenesis assay-Xenopus (FETAX):biotransformation and detoxification. Teratog Carcinog Mutagen 20:35-47.
16. Franks ME, Macpherson GR, Figg WD. 2004. Thalidomide. Lancet 363:1802-1811.
17. Gao X, Yourick JJ, Sprando RL. 2014. Embryonic stem cell differentiation and its modulation by developmental toxicants. PLoS One 9:e108510.
18. Hague DE, Idle JR, Mitchell SC, et al. 2011. Racemates revisited: heterochiral assemblies and the example of DL-thalidomide. Xenobiotica 41:837-843.
19. Hallene KL, Oby E, Lee BJ, et al. 2006. Prenatal exposure to thalidomide, altered vasculogenesis, and CNS malformations. Neuroscience 142:267-283.
20. Hamanishi C. 1980. Congenital short femur: clinical, genetic and epidemiological comparison of the naturally occurring condition with that caused by thalidomide. J Bone Joint Surg 62-B:307-320.
21. Hansen JM, Harris C. 2004. A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-kappaB pathway. Antioxid Redox Signal 6:1-14.
22. Hansen JM, Harris C. 2013. Redox control of teratogenesis. Reprod Toxicol 35:165-179.
23. Hansen JM, Gong SG, Philbert M, et al. 2002. Misregulation of gene expression in the redox-sensitive NF-kappab-dependent limb outgrowth pathway by thalidomide. Dev Dyn 225:186-194.
24. Hartmann MD, Boichenko I, Coles M, et al. 2014. Thalidomide mimics uridine binding to an aromatic cage in cereblon. J Struct Biol 188:225-232.
25. Higgins JJ, Pucilowska J, Lombardi RQ, et al. 2004. A mutation in a novel ATP-dependent lon protease gene in a kindred with mild mental retardation. Neurology 63:1927-1931.
26. Hootnick DR, Levinsohn EM, Randall PA, Packard DSJ. 1980. Vascular dysgenesis associated with skeletal dysplasia of the lower limb. J Bone Joint Surg Am 62:1123-1129.
27. Ito T, Ando H, Suzuki T, et al. 2010. Identification of a primary target of thalidomide teratogenicity. Science 327:1345-1350.
28. Ito T, Ando H, Handa H. 2011. Teratogenic effects of thalidomide: molecular mechanisms. Cell Mol Life Sci 68:1569-1579.
29. James WH. 1965. Teratogenetic properties of thalidomide. Br Med J 2:1064.
30. Jonsson NA. 1972. Chemical structure and teratogenic properties IV. An outline of a chemical hypothesis for the teratogenic action of thalidomide. Acta Pharm Suec 9:543-562.
31. Kajii T, Kida M, Takahashi K. 1973. The effect of thalidomide intake during 113 human pregnancies. Teratology 8:163-166.
32. Kelsey FO. 1988. Thalidomide update: regulatory aspects. Teratology 38:221-226.
33. Kenyon BM, Browne F, D'Amato RJ. 1997. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularisation. Exp Eye Res 64:971-978.
34. Knobloch J, Schmitz I, Gotz K, et al. 2008. Thalidomide induces limb anomalies by PTEN stabilization, akt suppression, and stimulation of caspase-dependent cell death. Mol Cell Biol 28:529-538.
35. Knobloch J, Jungck D, Koch A. 2011. Apoptosis induction by thalidomide: critical for limb teratogenicity but therapeutic potential in idiopathic pulmonary fibrosis? Curr Mol Pharmacol 4:26-61.
36. Knobloch J, Shaughnessy JD Jr, Ruther U. 2007. Thalidomide induces limb deformities by perturbing the bmp/dkk1/wnt signaling pathway. FASEB J 21:1410-1421.
37. Kohlhase J, Holmes LB. 2004. Mutations in sall4 in malformed father and daughter postulated previously to reflect mutagenesis by thalidomide. Birth Defects Res A 70:550-551.
38. Kohlhase J, Schubert L, Liebers M et al. 2003. Mutations at the sall4 locus on chromosone 20 result in a range of clinically overlapping phenotypes including okihiro syndrome, Holt-oram sundrome, acro-renal-ocular syndrome, and patients previously reported to represent thalidomdie embryopathy. J Med Genet 40:473-478.
39. Kronke J, Udeshi N, Narla A, et al. 2014. Lenalidomide causes selective degradation of ikzf1 and ikzf3 in multiple myeloma cells. Science 343:301-305.
40. Kusumbe AP, Ramasamy SK, Adams RH. 2014. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 507:323-328.
41. Lebrin F, Srun S, Raymond K, et al. 2010. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 16:420-428.
42. Lee CJJ, Goncalves LL, Wells PG. 2011. Embryopathic effects of thalidomide and its hydrolysis products in rabbit embryo culture: evidence for a prostaglandin H synthase (PHS)-dependent, reactive oxygen species (ROS)-mediated mechanism. FASEB J 25:2468-2483.
43. Lee KM, Yang SJ, Kim YD, et al. 2013. Disruption of the cereblon gene enhances hepatic AMPK activity and prevents High-fat Diet-induced obesity and insulin resistance in mice. Diabetes 62:1855-1864.
44. Lenz W. 1962. Thalidomide and congenital abnormalities. Lancet 1:271-272
45. Lenz W. 1988. A short history of thalidomide embryopathy. Teratology 28:203-215.
46. Lenz W, Knapp K. 1962. Foetal malformations due to Thalidomide. German Med. Monthly 7:253-258.
47. Levinsohn EM, Hootnick DR, Packard DSJ. 1991. Consistent arterial abnormalities associated with a varierty of congenital malformations of the human lower limb. Invest Radiol 26:364-373.
48. Li Y, Fu S, Chen H, et al. 2014. Inhibition of endothelial Slit2/Robo1 signalling by thalidomide restrains angiogenesis by blocking the PI3K/Akt pathway. Dig Dis Sci. 59:2958-2966.
49. Livingstone G. 1965. Congenital ear abnormalities due to thalidomide. Proc R Soc Med 58:493-497.
50. Love NR, Chen Y, Ishibashi S. et al. 2013. Amputation-induced reactive oxygen species are required for successful Xenopus tadpole tail regeneration. Nat. Cell Biol. 15:222-228.
51. Love NR, Chen Y, Bonev B. et al. 2011. Genome-wide analysis of gene expression during Xenopus tropicalis tadpole tail regeneration. BMC Dev Biol 11:70.
52. Lu G, Middleton RE, Sun H, et al. 2014. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins. Science 343:305-309.
53. McBride WG. 1976. Studies of the etiology of thalidomide dysmorphogenesis. Teratology 14:71-87.
54. McCredie J. 2009. History, heresy and radiology in scientific discovery. J Med Imaging Radiat Oncol 53:433-441.
55. McBride W. 1961. Thalidomide and congenital malformations. Lancet 1:358
56. McCredie J, McBride WG. 1973. Some congenital abnormalities: possibly due to embryonic peripheral neuropathy. Clin Radiol 24:204-211.
57. Mahony C, Erskine L, Niven J, et al. 2013. Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic invitro. Proc Natl Acad Sci USA 110:12703-12708.
58. Mahony C, Vargesson N. 2013. Molecular analysis of regulative events in the developing chick limb. J Anat 223:1-13.
59. Majumder S, Rajaram M, Muley A, et al. 2009. Thalidomide attenuates nitric oxide-driven angiogenesis by interacting with soluble guanylyl cyclase. Br J Pharmacol 158:1720-1734.
60. Mariani FV, Ahn C, Martin G. 2008. Genetic evidence that FGFs have an instructive role in limb proximal-distal patterning. Nature 453:401-405.
61. Meganathan K, Jagtap S, Wagh V, et al. 2012. Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells. PLoS One 7:e44228.
62. Merker HJ, Heger W, Sames K, et al. 1988. Embryotoxic effects of thalidomide-derivatives in the non-human primate callithrix jacchus. I. Effects of 3-(1, 3-dihydro-1-oxo-2H-isoindol-2-yl)-2, 6-dioxopiperidine (em12) on skeletal development. Arch Toxicol 61:165-179.
63. Miller MT, Stromland K. 1999. Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology 60:306-321.
64. Miller MT, Stromland K. 2011. What can we learn from the thalidomide experience: an ophthalmologic perspective. Curr Opin Opthalmol 22:356-364.
65. Miller MT, Stromland K, Ventura L, et al. 2005. Autism associated with conditions characterised by developmental errors in early embryogenesis: a mini-review. Int J Dev Neuro 23:201-219.
66. Miller MT., Ventura L., Stromland K. 2009. Thalidomide and misoprostol: Ophthalmologic manifestations and associations both expected and unexpected. Birth Defects Res A Clin Mol Teratol 85:667-676.
67. Monnich M, Kuriger Z, Print CG, Horsfeld JA. 2011. A zebrafish model of roberts syndrome reveals that esco2 depletion interferes with development by disrupting the cell cycle. PLoS One 6:e20051. Article ID 2011.
68. Moreira AL, Sampaio EP, Zmuidzinas A, et al. 1993. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675-1680.
69. Newman CG. 1977. Clinical observations on the thalidomide syndrome. Proc R Soc Med 70:225-227.
70. Newman CGH. 1985. Teratogen update: clinical aspects of thalidomide embryopathy-a continuing preoccupation. Teratology 32:133-144.
71. Newman CGH. 1986. The thalidomide syndrome: risks of exposure and spectrum of malformations. Clin Perinatol 13:555-573.
72. Newman RJ. 1999. Shoulder joint replacement for osteoarthrosis in association with thalidomide-induced phocomelia. Clin Rehabil 13:250-252.
73. Ng SS, Gutschow M, Weiss M, et al. 2003. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res 63:3189-3194.
74. Niemann S., Zhao C., Pascu F., et al., 2004. Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous family. Am J Hum Genet 74:558-563.
75. Nowack E. 1965. The sensitive phase in thalidomide embryopathy. Humangenetik 1:516-536. (article in German).
76. Ornoy A, Reece EA, Pavlinkova G., et al. 2015. Effect of maternal diabetes on the embryo, fetus, and children: congenital anomalies, genetic and epigenetic changes and developmental outcomes. Birth Defects Res C Embryo Today 105:53-72.
77. Packard DS Jr, Levinsohn EM, Hootnick DR. 1991 Teratological implications of soft tissue abnormalities found in human lower limbs with bony defects. In: Feinberg RN, Sherer DK, Auerbach R, editors. Development of the Vascular System. Issues in Biomedicine. New York. Karger. pp. 157-169.
78. Parman T, Wiley MJ, Wells PG. 1999. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 5:582-585.
79. Price DK, Ando Y, Kruger EA, Weiss M, Figg WD. 2002. 5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis. Ther Drug Monit 24:104-110.
80. Ramasamy SK, Kusumbe AP, Wang L, Adams RH. 2014. Endothelial notch activity promotes angiogenesis and osteogenesis in bone. Nature 507:376-380.
81. Rashid A, Kuppa A, Kunwar A, et al. 2015. Thalidomide (5HPP-33) suppresses microtubule dynamics and depolymerizes microtubule network by binding at vinblastine binding site on tubulin. Biochemistry 54:2149-2159.
82. Ruffing L. 1977. Evalulation of thalidomide children. Birth Defects Orig Artic Ser 13:287-300.
83. Schmidt M, Salzano FM. 1980. Dissimilar effects of thalidomide in dizygotic twins. Acta Genet Med Gemellol (Roma) 29:295-297.
84. Schmidt M, Salzano FM. 1983. Clinical studies on teenage brazilian victims of thalidomide. Brazilian. J Med Biol Res 16:105-109.
85. Schule A, Oviedo A, Johnston K, Pai S, Francker U. 2005. Inactivating mutations in esco2 causes SC phocomelia and roberts syndrome: no phenotype-genotype correlation. Am J Hum Genet 77:1117-1128.
86. Schuler-Faccini L, Soares RC, de Sousa AC, et al. 2007. New cases of thalidomide embryopathy in Brazil. Birth Defects Res A Clin Mol Teratol 79:671-673.
87. Sheskin J. 1965. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6:303-306.
88. Siamwala JH, Veeriah V, Priya MK, et al. 2012. Nitric oxide rescues thalidomide mediated teratogenicity. Sci Rep 2:679. article
89. Smith RL, Fabro S, Schumacher H, et al. 1965. Studies on the relationship between the chemical structure and embryotoxic activity of thalidomide and related compounds. In: Robson JM, Sullivan, F, Smith, RL, editors. Embryopathic activity of drugs. London: Churchill Ltd. pp. 194-209.
90. Smithells RW. 1962. Thalidomide and malformations in liverpool. Lancet 1:1270-1273.
91. Smithells RW. 1973. Defects and disabilities of thalidomide children. Br Med J 1:269-272.
92. Smithells RW, Leck I. 1963. The incidence of limb and ear defects since the withdrawal of thalidomide. Lancet 1:1095-1097.
93. Smithells RW, Newman CGH. 1992. Recognition of thalidomide defects. J Med Genet 29:716-723.
94. Somers GS. 1962. Thalidomide and congenital abnormalities. Lancet 1:912-913.
95. Soules BJ. 1966. Thalidomide victims in a rehabilitation centre. Ha-Ahot be-Yisrael 12:43-45.
96. Spiers AL. 1962. Thalidomide and congenital abnormalities. Lancet 1:303-305.
97. Stephens TD. 1988. Proposed mechanisms of action in thalidomide embryopathy. Teratology 38:229-239.
98. Stephens TD. 2009. The effect of thalidomide in chicken embryos. Birth Defects Res A 85:725-731.
99. Stephens TD, Fillmore BJ. 2000. Hypothesis: thalidomide embryopathy-proposed mechanism of action. Teratology 61:189-195.
100. Stephens TD, Bunde CJ, Fillmore BJ. 2000. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 59:1489-1499.
101. Stromland K, Philipson E, Andersson Gronlund M. 2002. Offspring of male and female parents with thalidomide embryopathy: birth defects and functional anomalies. Teratology 66:115-121.
102. Stromland K., Miller MT. 1992. Refractive evaluation in thalidomide embryopatny. Graefes Arch Clin Exp Ophthalmol 230:140-149.
103. Tamilarasan KP, Kolluru GK, Rajaram M, et al. 2006. Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells. BMC Cell Biol 7:17.
104. Taussig HB. 1962. A study of the german outbreak of phocomelia. The thalidomide syndrome. JAMA 180:1106-1114.
105. Therapontos C, Erskine L, Gardner E, et al. 2009. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci USA 106:8573-8578.
106. Uhl K, Cox E, Rogan R, et al. 2006. Thalidomide use in the US: experience with pregnancy testing in the STEPS prrogramme. Drug Safety 29:321-329.
107. UK Government Report. 1964. Deformities caused by Thalidomide. In: Reports on Public Health and Medical Subjects. No. 112. ed. Ministry of Health. London: HMSO
108. Vargesson N. 2003. Vascularization of the developing chick limb bud: role of the TGFbeta signalling pathway. J Anat 202:93-103.
109. Vargesson N. 2009. Thalidomide-induced limb defects: resolving a 50-year-old puzzle. BioEssays 31:1327-1336.
110. Vargesson N. 2013. Thalidomide embryopathy: an enigmatic challenge. ISRN Dev Biol 2013:1-18. doi:10.1155/2013/241016
111. Vargesson N, Laufer E. 2001. smad7 misexpression during embryonic angiogenesis causes vascular dilation and malformations independently of vascular smooth muscle cell function. Dev Biol 240:499-516.
112. Vega H, Waisfisz Q, Gordillo M, et al. 2005. Roberts syndrome is caused by mutations in esco2, a human homolog of yeast eco1 that is essential for the establishment of sister chromatid cohesion. Nat Genet 37:468-470.
113. Vianna FS, Schuler-Faccini L, Leite JC, et al. 2013. Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy: new cases and review of the main dysmorphological findings. Clin Dysmorphol 22:59-63.
114. Wells PG., McCallum GP., Chen CS et al., Oxidative stress in developmental origins of disease: teratogenesis, neurodevelopmental deficits, and cancer. 2009. Toxicological Sciences 108:4-18.
115. Whelan G, Kreidl E, Peters JM, Eichele G. 2012. The non-redundant function of cohesin acetyle transferase esco2: some answers and new questions. Nucleus 3:330-334.
116. Whitsel AI, Johnson CB, Forehand CJ. 2002. An in ovo chicken model to study the systemic and localized teratogenic effects of valproic acid. Teratology 66:153-163.
117. Yabu T, Tomimoto H, Taguchi Y, et al. 2005. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 106:125-134.
118. Zeldis JB, Williams BA, Thomas SD, et al. 1999. STEPS: a comprehensive program for controlling amnd monitoring access to thalidomide. Clin Thera 21:319-330.
119. Zhao X, Jiang B, Hu H, et al. 2015. Zebrafish cul4a, but not cul4b, modulatescardiac and forelimb development by upregulating tbx5a expression. Hum Mol Gen 24:853-864.